MarginsXMarginsX
Home › Markets › IDXG

Interpace Biosciences Inc. (IDXG)

IDXG trades on OTC. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$6.20
+2.48% on the day
Market cap
$25.1M
Nano cap
Revenue · 2025
$38.7M
-17.5% on 2024
Net income · 2025
$24.6M
63.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1054102/000149315226013646/0001493152-26-013646-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerIDXG on OTC
SectorThe Nasdaq screener gives no sector
IndustryThe Nasdaq screener gives no industry
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001054102
SEC industry codeSurgical & Medical Instruments & Apparatus
Incorporated inDE

Financials · 2025

LineValue
Revenue$38.7M
Net income$24.6M
Operating income$4.1M
Net margin63.5%
Operating margin10.5%
Revenue growth-17.5%
Cash$2.5M
Total assets$33.8M
P/E (computed)1.0×
P/S (computed)0.6×

Warning signs

Cash runway
Cash-flow positive
$2.7M cash at June 30, 2026
Share count, 1 year
+526.3%
2025-08-01 to 2026-07-31 · +542.1% over 3 years
Going-concern doubt
No
10-Q filed August 10, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-08-10
Cash and burn$2.7M cash; operating cash flow $1.1M a quarter.Report 2026-06-30
Shares outstanding27,700,904 (2026-07-31); 4,423,093 a year earlier; 4,314,216 three years earlier.Cover page 2026-07-31
Reverse splits, 3 years1; latest on 2026-08-27Source 2026-08-27
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorEisnerAmper LLP, Philadelphia, Pennsylvania, United StatesPCAOB Form AP 2026-03-31
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30
Market cap checkThe listing's market cap implies 4,055,593 shares at the 2026-11-13 price; the latest SEC cover count is 27,700,904 as of 2026-07-31. One of the two share counts is stale.Nasdaq screener and SEC cover page

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q2 2026
2026-06-30
$9.1M$158K$98K$2.7MNo debt tags$36.1M10-Q 2026-08-10
Q1 2026
2026-03-31
$9.0M$721K$283K$2.6MNo debt tags$36.2M10-Q 2026-05-12
Q4 2025
2025-12-31
$9.2M$22.7M$2.1M$2.5M$0$38.7M10-K 2026-03-30
Q3 2025
2025-09-30
$8.8M$911K$1.9M$1.4M$2.0M$41.9M10-Q 2025-11-12
Q2 2025
2025-06-30
$9.2M-$640K$520K$502K$3.7M$45.5M10-Q 2026-08-10
Q1 2025
2025-03-31
$11.5M$1.6M$1.2M$1.2M$5.7M$48.3M10-Q 2026-05-12
Q4 2024
2024-12-31
$12.4M$1.9M$1.2M$1.5M$8.7M$46.9M10-K 2026-03-30
Q3 2024
2024-09-30
$12.3M$1.7M$2.1M$1.4M$11.6M$44.6M10-Q 2025-11-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-1/A2026-10-30
Latest annual report10-K/A2026-04-30
Latest quarterly / interim10-Q2026-11-16
Latest current report8-K2026-10-15
Latest proxyDEFA14A2026-07-07

Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-13.6%
1 month+2.5%
3 months+262.3%
Year to date+391.9%
1 year+523.7%
From 52-week high-20.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers

No industry from the screener, so peers can't be matched.

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier